Induction of human papillomavirus-specific CD4+ and CD8+ lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer

Journal of Virology

Volumn 73, Issue 7, 1999, Pages 5402-5410

  Santin, Alessandro D ^a,b,c   Hermonat, Paul L ^a   Ravaggi, Antonella ^a,b   Chiriva Internati, Maurizio ^a,b   Zhan, Dejin ^a   Pecorelli, Sergio ^b   Parham, Groesbeck P ^a   Cannon, Martin J ^a  

^a UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF ARKANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HLA A2 ANTIGEN; HLA ANTIBODY; INTERLEUKIN 4; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; PROTEIN E7; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CELL MEDIATED CYTOTOXICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; UTERINE CERVIX CARCINOMA; VIRUS STRAIN; WART VIRUS;

EID: 0033056681     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.7.5402-5410.1999     Document Type: Article

References (51)

1. Alexander, M., M. L. Salgaller, E. Celis, A. Sette, W. A. Barnes, S. A. Rosenberg, and M. A. Steller. 1996. Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope. Am. J. Obstet. Gynecol. 175:1586-1593.
2. d-restricted cytotoxic T lymphocytes. J. Exp. Med. 173:849-858.
3. Alexander-Miller, M. A., G. R. Leggatt, and Y. A. Berzofsky. 1996. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA 93:4102-4107.
4. Antinore, M. J., M. J. Birrer, D. Patel, L. Nader, and D. J. McCance. 1996. The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP1 family of transcription factors. EMBO J. 15:1950-1960.
5. Bal, V., A. McIndoe, D. Hudson, G. Lombardi, J. Lamb, and R. Lechler. 1990. Antigen presentation by keratinocytes induces tolerance in human T cells. Eur. J. Immunol. 20:1893-1897.
6. Baskar, S., V. Azarenko, E.-G. Marshall, E. Hughes, and S. Ostrand-Rosenberg. 1994. MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous mice. Cell. Immunol. 155:123-133.
7. Baskar, S., L. Glimcher, N. Nabavi, R. T. Jones, and S. Ostrand-Rosenberg. 1998. Major histocompatibility complex class II+ B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor bearing mice. J. Exp. Med. 181:619-629.
8. Bennett, S. R. M., F. R. Carbone, F. Karamalis, J. F. A. P. Miller, and W. R. Heath. 1997. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J. Exp. Med. 186:65-70.
9. Beverly, P. C., E. Sadovnikova, X. Zhu, J. Hickling, L. Gao, S. Collins, L. Crawford, K. Vousden, and H. J. Status. 1994. Strategies for studying mouse and human immune responses to human papillomavirus type 16. Ciba Found. Symp. 187:78-86.
10. Borysiewicz, L. K., A. Fiander, M. Nimako, S. Man, G. W. G. Wilkinson, D. Westmoreland, A. S. Evans, M. Adams, S. N. Stacey, M. E. G. Boursnell, E. Rutherford, J. K. Hickling, and S. C. Inglis. 1996. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347:1523-1527.
11. Bosh, F. X., M. M. Manos, N. Munoz, M. Sherman, A. M. Jansen, J. Peto, M. H. Schiffman, V. Moreno, R. Kurman, and K. V. Shah. 1995. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J. Natl. Cancer Inst. 87:796-802.
12. Brinton, L. A. 1992. Epidemiology of cervical cancer: overview. IARC Sci. Publ. 119:3-23.
13. Carbone, F. R., M. W. Moore, J. M. Shell, and M. J. Bevan. 1998. Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides. J. Exp. Med. 167:1767-1779.
14. Chen, L., E. K. Thomas, S.-L. Hu, I. Hellstrom, and K. E. Hellstrom. 1991. Human papilloma virus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc. Natl. Acad. Sci. USA 88:110-114.
15. Chen, L., M. T. Mizuno, M. C. Singal, S.-L. Hu, D. A. Galloway, I. Hellstrom, and K. E. Hellstrom. 1992. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papilloma virus type 16. J. Immunol. 148:2617-2621.
16. Clerici, M., M. Merola, E. Ferrario, D. Trabattoni, M. L. Villa, B. Stefanon, D. J. Venzon, G. M. Shearer, G. De Palo, and E. Clerici. 1997. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J. Natl. Cancer Inst. 89:245-250.
17. Connor, M. E., and P. L. Stern. 1990. Loss of MHC class-I expression in cervical carcinomas. Int. J. Cancer 46:1029-1034.
18. De Bruijn, M. L. H., D. H. Schuurhuis, M. P. M. Vierboom, H. Vermeulen, K. A. J. de Cock, M. E. Ooms, M. E. Ressing, M. Toebes, K. L. M. C. Franken, J.-W. Drijfhout, T. H. M. Ottenhoff, R. Offringa, and C. J. M. Melief. 1998. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I restricted protection to HPV16-induced tumor cells. Cancer Res. 58:724-731.
19. Evans, E. M.-L., S. Man, A. S. Evans, and L. K. Borysiewicz. 1997. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res. 57:2943-2950.
20. Fujinaga, Y., M. Shimada, K. Okazawa, M. Fukushima, I. Kato, and K. Fujinaga. 1991. Simultaneous detection and typing of genital human papillomavirus DNA using the polymerase chain reaction. J. Gen. Virol. 72:1039-1044.
21. Guan, K., and J. E. Dixon. 1991. Eukaryotic proteins expressed in Escherichia coli: an improved thrombin cleavage and purification procedure of fusion proteins with glutathione-S-transferase. Anal. Biochem. 192:262-267.
22. Higgins, G. D., D. M. Uzelin, G. E. Phillips, P. McEvoy, R. Marin, and C. J. Burrel. 1992. Transcription pattern of human papillomavirus type 16 in genital intraepithelial neoplasia: evidence for promoter usage within the E7 open reading frame during epithelial differentiation. J. Gen. Virol. 73:2047-2057.
23. Hilders, C. G. J. M., L. Ras, J. D. H. Van Eendenburg, Y. Nooyen, and G. J. Fleuren. 1994. Isolation and characterization of tumor-infiltrating lymphocytes from cervical carcinoma. Int. J. Cancer 57:805-813.
24. Honma, S., S. Tsukada, S. Honda, M. Nakamura, K. Takakuwa, T. Maruhashi, S. Kodama, K. Konazawa, T. Takahashi, and K. Tanaka. 1994. Biological-clinical significance of selective loss of HLA-class I allelic product expression in squamous-cell carcinoma of the uterine cervix. Int. J. Cancer 57:650-655.
25. Hopkins, K. A. 1990. Basic microlymphocytotoxicity test, p. 195-201. In ASHI laboratory manual. American Society for Histocompatibility and Immunogenetics, Lenexa, Kans.
26. Hsu, F. J., C. Benike, F. Fagnoni, T. M. Liles, D. Czerwinski, B. Taidi, E. G. Engleman, and R. Levy. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:52-58.
27. Huang, A. Y. C., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky. 1994. Role of bone-marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961-965.
28. Jochmus, I., W. Osen, A. Altmann, B. Hofmann, A. Schneider, L. Gissmann, and H.-G. Rammensee. 1997. Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide. J. Gen. Virol. 78:1689-1695.
29. McIntyre, M. C., M. N. Ruesch, and L. A. Laimins. 1996. Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with cdk2 and p107. Virology 215:73-82.
30. Meneguzzi, G., C. Cerni, M. P. Kieny, and R. Lathe. 1991. Immunization against human papilloma virus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology 181:62-69.
31. Motero, I., M. C. Singhal, P. McGowan, H. S. Haugen, J. Blake, K. E. Hellstrom, G. Yang, C. H. Clegg, and L. Chen. 1997. Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16. J. Virol. 71:3998-4004.
32. Nasiell, K., V. Roger, and M. Nasiell. 1986. Behaviour of mild cervical dysplasia during long term follow-up. Obstet. Gynecol. 67:665-669.
33. Nazaruk, R. A., R. Rochford, M. V. Hobbs, and M. J. Cannon. 1998. Functional diversity of the CD8+ T cell response to Epstein-Barr virus (EBV): implications for the pathogenesis of EBV-associated lymphoproliferative disorders. Blood 91:3875-3883.
34. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328-332.
35. Nikoloff, B. J., and L. A. Turka. 1994. Immunological functions of nonprofessional antigen-presenting cells: new insights from studies of T-cell interactions with keratinocytes. Immunol. Today 15:464-469.
36. Nimaco, M., A. N. Fiander, G. W. G. Wilkinson, L. K. Borysiewicz, and S. Man. 1997. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III. Cancer Res. 57:4855-4861.
37. Openshaw, P. J. M., E. E. Murphy, N. A. Hosken, V. Maino, K. Davis, K. Murphy, and A. O'Garra. 1995. Heterogeneity of intracellular cytokine synthesis at the single cell level in polarized T helper 1 and T helper 2 populations. J. Exp. Med. 182:1357-1364.
38. Ossendorp, F., E. Mengedé, M. Camps, R. Filius, and C. J. M. Melief. 1998. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187:693-702.
39. Penn, I. 1988. Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer 53:539-545.
40. Pulaski, B. A., and S. Ostrand-Rosenberg. 1998. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and 7.1 cell-based tumor vaccines. Cancer Res. 58:1486-1493.
41. Rellihan, M. A., D. P. Dooley, T. W. Burke, M. E. Berkland, and R. N. Longfield. 1990. Rapidly progressing cervical cancer in a patient with human immunodeficiency virus infection. Gynecol. Oncol. 36:435-438.
42. Ressing, M. E., A. Sette, R. M. Brandt, J. Ruppert, P. A. Wentworth, M. Hartman, C. Oseroff, H. M. Grey, C. J. Melief, and W. M. Kast. 1995. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*201-binding peptides. J. Immunol. 154:5934-5943.
43. Romagnani, S. 1992. Human TH1 and TH2 subsets: regulation of differentiation and role in protection and immunopathology. Int. Arch. Allergy Immunol. 98:279-285.
44. Romani, N., S. Gruner, D. Brang, E. Kampgen, A. Lenz, B. Trockebacher, G. Konwalinka, P. O. Fritsch, R. M. Steinman, and G. Schuler. 1994. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180:83-93.
45. Steinman, R. A. 1991. The dendritic cell system and its role in immunogenicity. Ann. Rev. Immunol. 9:271-296.
46. Stoler, M. H., C. R. Rhodes, A. Whitbeck, S. M. Wolinsky, L. T. Chow, and T. R. Brocker. 1992. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum. Pathol. 23:117-128.
47. Thiele, D. L., and P. E. Lipsky. 1989. The role of cell surface recognition structures in the initiation of MHC-unrestricted "promiscuous" killing by T cells. Immunol. Today 10:375-381.
48. Tsukui, T., A. Hildesheim, M. H. Schiffman, J. Lucci III, D. Contois, P. Lawler, B. B. Rush, A. T. Loricz, A. Corrigan, R. D. Burk, W. Qu, M. A. Marshall, D. Mann, M. Carrington, M. Clerici, G. M. Shearer, D. P. Carbone, D. R. Scott, R. A. Houghten, and J. A. Berzofsky. 1996. Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology. Cancer Res. 56:3967-3974.
49. Vitiello, A., G. Ishioka, H. M. Grey, R. Rose, P. Farness, R. LaFond, L. Yuan, F. V. Chisari, J. Furze, R. Bartholomeuz, and R. W. Chesnut. 1995. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Investig. 95:341-349.
50. Walter, E. A., P. D. Greenberg, M. J. Gilbert, R. J. Finch, K. S. Watanabe, E. D. Thomas, and S. R. Riddell. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1038-1044.
51. Young, J. W., and K. Inaba. 1996. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J. Exp. Med. 183:7-11.